Lilly JAK inhibitor cuts covid death risk

 

• According to a British study, Eli Lilly And Co 
  LLY +1.66%
   (Get Free Alerts for LLY) and Incyte Corporation's 
  INCY -1.24%
   (Get Free Alerts for INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%.
• According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial.
• Results showed that 546 patients in the standard of care group died within 28 days, compared to 513 patients in the baricitinib group who died where they were also given a corticosteroid like dexamethasone, tocilizumab, or remdesivir.
• "This result confirms and extends earlier findings, providing greater certainty that baricitinib is beneficial and new data to guide the treatment of COVID-19 patients with a combination of drugs to dampen the immune response," said Peter Horby, Oxford professor and joint chief investigator.
• In the RECOVERY trial, baricitinib also increased the chances of patients being discharged alive within 28 days and reduced the risk of their condition worsening, scientists said.

https://www.benzinga.com/general/biotech/22/03/25970443/eli-lillys-jak-inhibitor-baricitinib-cuts-death-risk-by-13-in-covid-19-patients